No Data
No Data
No Data
No Data
No Data
Grand Pharmaceutical Group Limited (HKG:512) Insiders Have Had a Fantastic Week as Stock Increased 6.8%, and They Haven't Stopped Buying
Key Insights Insiders appear to have a vested interest in Grand Pharmaceutical Group's growth, as seen by their sizeable ownership A total of 2 investors have a majority stake in the company with 59
Simply Wall StApr 12 18:52 ET
Yuanda Pharmaceutical (00512.HK) was increased by 101,000 shares by Executive Director Zhou Chao
Gelonghui, April 10 | According to the latest equity disclosure data of the Stock Exchange, on April 8, 2024, Yuanda Pharmaceutical (00512.HK) was granted an increase of 101,000 shares by Executive Director Zhou Chao at an average price of HK$3955 per share on the market, involving about HK$39,500. After increasing his holdings, Zhou Chao's latest shareholding was 263,000 shares.
Gelonghui FinanceApr 9 18:48 ET
Yuanda Pharmaceutical (00512.HK) introduces innovative global products to treat demodex mite blepharitis and meibomian gland dysfunction caused by demodex
Gelonghui, March 27 | Yuanda Pharmaceutical (00512.HK) announced that the Group reached a strategic cooperation agreement with Liantuo Biotechnology Co., Ltd. and Tarsus Pharmaceuticals, Inc. (“Tarsus”). After the relevant conditions are met, the Group will obtain exclusive rights for the development, production and commercialization of TP-03, a globally innovative ophthalmic formulation for the treatment of demodex blepharitis and meibomian gland dysfunction caused by demodex mite in Greater China at the cost of a down payment of US$15 million and a certain registration milestone fee. this
Gelonghui FinanceMar 27 05:26 ET
Changes in Hong Kong stocks | Yuanda Pharmaceutical (00512) rose more than 5%, and a new drug to treat gastrointestinal and pancreatic neuroendocrine tumors was approved for phase III clinical trials
Yuanda Pharmaceutical (00512) rose more than 5% in early trading, and climbed about 15% after the results. As of press release, it rose 5.06% to HK$4.15, with a turnover of HK$8.2581 million.
Zhitong FinanceMar 25 23:46 ET
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug
Grand Pharmaceutical Group (HKG:0512) said China's National Medical Products Administration (NMPA) approved its drug ITM-11 to proceed to Phase III clinical trials, according to a Hong Kong bourse fil
MT NewswiresMar 24 22:57 ET
Yuanda Pharmaceutical (00512.HK) was increased by 106,000 shares by Executive Director Zhou Chao
Gelonghui, March 25 | According to the latest equity disclosure data of the Stock Exchange, from March 21 to March 22, 2024, Yuanda Pharmaceutical (00512.HK) obtained executive director Zhou Chao increased his holdings by a total of 106,000 shares at an average price of HK$4.03-4.05 per share on the market, involving approximately HK$428,000. After increasing his holdings, Zhou Chao's latest shareholding was 162,000 shares.
Gelonghui FinanceMar 24 18:38 ET
No Data
No Data